Zurich Cantonal Bank’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Zurich Cantonal Bank’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,420	Closed	-$8K	–	2938
2022 Q3	$8K	Hold	3,420	–	–	﹤0.01%	2874
2022 Q2	$10K	Sell	3,420 -399	-10%	-$1.94K	﹤0.01%	2856
2022 Q1	$26K	Buy	+3,819	New	+$27.2K	﹤0.01%	2642
2018 Q4	–	Sell	-1,735	Closed	-$11K	–	2603
2018 Q3	$11K	Hold	1,735	–	–	﹤0.01%	2538
2018 Q2	$13K	Buy	+1,735	New	+$25K	﹤0.01%	2472

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Zurich Cantonal Bank's JNCE Position: Q4 2022 in Review

Zurich Cantonal Bank sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 3,420 shares — an estimated $8K sold.

Zurich Cantonal Bank first reported a position in JNCE in Q2 2018 and held it in 5 quarters. The position peaked at $26K in Q1 2022. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

Zurich Cantonal Bank reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Zurich Cantonal Bank sold 3,420 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $8K.
Zurich Cantonal Bank first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
Zurich Cantonal Bank's Jounce Therapeutics, Inc. Common Stock position peaked at $26K in Q1 2022.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Zurich Cantonal Bank's 13F filing for Q4 2022, filed 1 Feb 2023.